Edward Fiorentino has sold SENS and made no open-market buys since May 2021

Edward J. Fiorentino is a seasoned healthcare and specialty pharmaceuticals executive and independent director of Senseonics Holdings, Inc., where he has served on the Board of Directors since December 2015.( As a non‑employee director, he participates in Senseonics’ equity-based compensation program and has reported multiple Form 4 transactions related to option and restricted stock unit grants, reflecting his ongoing role in the company’s corporate governance.( In 2023, he received total compensation of approximately $169,000 in his capacity as an independent director.(

Fiorentino is currently Executive Chairman of TerSera Therapeutics, a specialty pharmaceutical company, after previously serving as its Chairman and Chief Executive Officer from the company’s inception in 2016 through December 2023.( Before TerSera, he was Chairman and CEO of Crealta Pharmaceuticals and CEO of Actient Pharmaceuticals, following more than 20 years in senior leadership roles at Abbott Laboratories, including Corporate Vice President of Pharmaceutical Commercial Operations, Senior Vice President and President of Abbott Diabetes Care, and Executive Vice President of TAP Pharmaceuticals.( He began his career with Bristol‑Myers and has held numerous board positions in healthcare and life sciences organizations.( Fiorentino holds a B.S. in Business Administration from the State University of New York and an M.B.A. from Syracuse University.(

Written by Perplexity from public sources.